The FDA updated the Levaquin label last week.

 June 28, 2019, the FDA updated the Levaquin label MEDICATION GUIDE which is the information given to patients.

The FDA added more psychiatric adverse event warnings to the MEDICATION GUIDE including:

  • Feeling agitated
  • Reduced awareness of surroundings
  • Memory problems
  • False or strange thoughts or beliefs (delusions)

The June 28, 2019 MEDICATION GUIDE also now states that “Tendon problems may be permanent.”